Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ompetition, and others stated in risk factors contained in our SEC filings.  We cannot assure that we have identified all risks or that others may emerge which we do not anticipate.  You should not place undue reliance on forward-looking statements.  Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Galectin Therapeutics and its associated logo is a trademark of Galectin Therapeutics Inc.

 Condensed Consolidated Statements of OperationsThree Months
EndedDecember 31,Twelve MonthsEndedDecember 31,2012201120122011(in thousands, except per share data)

(unaudited)Operating expenses:  Research and development

$1,002

$862

$4,527

$3,552  General and administrative

1,380

2,510

5,372

6,857  Total operating expenses

2,382

3,372

9,899

10,409Total operating loss

(2,382)

(3,372)

(9,899)

(10,409)Other income and (expense):  Interest income

6

4

24

18  Change in fair value of warrant liabilities

-

-

-

(524)  Other income

-

-

200

-Total other income (expense)

6

4

224

(506)Net loss

$(2,376)

$(3,368)

$(9,675)

$(10,915)Preferred stock dividends and accretion costs

(332)

(350)

(1,206)

(1,798)Net loss applicable to common stock

$(2,708)

$(3,718)

$(10,881)

$(12,713)Basic and diluted net loss per share

$  (0.17)

$  (0.29)

$  (0.72)

$  (1.06)Shares used in computing basic and diluted net loss per share

15,966

12,846

15,131

11,986 Condensed Consolidated Balance She
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Mathematic studies at the Program for Evolutionary Dynamics ... Jeffrey Epstein VI Foundation , have shown that the ... elimination. These aggressive cells are the driver mutations that drive ... of what to look for when examining tumors, comes at ... can be extracted from biopsy, it,s very difficult to know ...
(Date:8/21/2014)... VIEW, Calif. , Aug. 21, 2014 /PRNewswire/ ... properties and behaviors based on external stimuli such ... poised to have a disruptive effect in multiple ... revolutionize the business landscape by printing objects ranging ... aerospace and automotive sectors. Logo - ...
(Date:8/21/2014)... 2014 Gallus BioPharmaceuticals , ... and manufacturing organization (CMO) announced today that it ... oncology company focused on the development of innovative ... the anti-prostate specific membrane antigen (PSMA) monoclonal antibody ... Under the agreement the antibody will be produced ...
(Date:8/20/2014)... N.C. , Aug. 20, 2014 ... research services located in Raleigh, NC ... Bradford Evans as Vice President of Administration. ... Brad will oversee all corporate processes, including their ... joining Clintrax Global, Brad worked as an HR ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Clintrax Global, Inc. Announces Addition to Executive Team 2
... Could Drive Product Adoption in High-Growth Cell Therapy Market ... Dec. 16 BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), ... storage and cryopreservation media products for cells, tissues, and ... series of small animal safety studies at the Seattle-based ...
... Epeius Biotechnologies,Corporation, a leader in tumor-targeted gene ... for the platform targeting technologies and,molecular designs ... cancers and,metastatic lesions that have spread throughout ... and single-agent-efficacy, as well as,overall safety, Epeius ...
... SOUTH SAN FRANCISCO, Calif., Dec. 16 Anesiva,Inc. ... results showing that the Phase 3,trial evaluating Adlea(TM), ... efficacy endpoint of reducing post-surgical,pain versus placebo (p=0.03) ... surgery) at four to 48 hours after surgery. ...
Cached Biology Technology:BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM) 2BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM) 3BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM) 4Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate 2Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 2Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 3Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 4
(Date:8/22/2014)... . , Thanks ... in a way so as to align themselves symmetrically, ... University researchers are planning on looking into how PCFs ... being published today in the scientific journal Nature ... Everyone knows that at least from having boiled ...
(Date:8/22/2014)... tea polyphenols are strong antioxidants and can ... spinal cord neurons against oxidative stress? Jianbo ... Hospital of Liaoning Medical University, China discovered ... stress and inhibit neuronal apoptosis, indicating green ... spinal cord neurons under oxidative stress. The ...
(Date:8/22/2014)... 2015, American consumers will finally be able to purchase ... touted as zero-emissions vehicles, most of the cars will ... fuel that contributes to global warming. , Now scientists ... that uses an ordinary AAA battery to produce hydrogen ... current through two electrodes that split liquid water into ...
Breaking Biology News(10 mins):Proteins: New class of materials discovered 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3
... , Sept. 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a ... drug development services to industry, announced today that they ... an investigational medication for Type 2 Diabetes Mellitus.  The ... tolerability of multiple daily doses of the investigational medication ...
... chemical engineering researchers have created a new synthetic metabolic pathway ... percent increase in the production of biofuels. ... pathway known as glycolysis, a series of chemical reactions that ... precursors that cells need. Glycolysis converts four of the six ...
... has detected propylene, a chemical used to make food-storage ... moon Titan. This is the first definitive detection ... other than Earth. A small amount of propylene ... Infrared Spectrometer (CIRS). This instrument measures the infrared light, ...
Cached Biology News:Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication 2UCLA engineers develop new metabolic pathway to more efficiently convert sugars into biofuels 2NASA's Cassini spacecraft finds ingredient of household plastic in space 2
... The Fujifilm Life Science FLA-7000 excels at ... CBB-stained gel documentation. It features four easy-to-access ... and a filter for Imaging Plates) for ... a customizable choice of four kinds of ...
... has been optimized for the analysis of ... software to quickly and accurately locate and ... an ELISA plate or each section of ... been customized to incorporate standard ELISA analysis ...
For microscopy...
... General description: Humidity wells in the ... maintain chamber humidity and probe hydration around ... seal eliminates the risk of waterbath contamination. ... constant temperature waterbaths or hybridisation ovens. Linkage: ...
Biology Products: